Intuitive Surgical Faces Competition from Medtronic's New Surgical Robot
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ISRG?
Source: NASDAQ.COM
- Increased Market Competition: Intuitive Surgical has 11,395 da Vinci systems installed globally, a 12% year-over-year increase, while Medtronic has just launched its Hugo surgical robot, which could become a significant growth engine in the coming years, intensifying market competition.
- Revenue Structure Analysis: In Q1, only 24% of Intuitive Surgical's revenue came from new system sales, with the remainder from services and accessories, highlighting the strength of its business model, although with a high P/E ratio of 55, investors should proceed with caution.
- Stock Price Volatility Risk: Despite a 500% increase in Intuitive Surgical's stock price over the past decade, it has recently fallen over 20% from its 52-week high, indicating potential volatility risks associated with high valuations, particularly for conservative investors.
- Dividend Appeal: Medtronic offers a dividend yield of 3.6% and has increased its dividend for 48 consecutive years, demonstrating business stability and attractiveness, especially for conservative investors during periods of market volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 453.490
Low
575.00
Averages
637.32
High
740.00
Current: 453.490
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Comparative Analysis of Intuitive Surgical and Medtronic
- Business Model Advantage: Intuitive Surgical has installed 11,395 da Vinci surgical systems globally, reflecting a 12% year-over-year increase, while demand for robotic-assisted surgeries has surged by 17%, indicating strong market demand and sustained revenue potential.
- Revenue Structure Analysis: In Q1, only 24% of Intuitive Surgical's revenue came from new system sales, with the remainder driven by services and accessories, highlighting a business model reliant on ongoing service income that enhances the company's long-term financial stability.
- Market Opportunity for Medtronic: Medtronic's recently launched Hugo surgical robot is beginning to ramp up sales, and despite a 40% drop from its 2021 peak, its diversified business and stable dividend appeal to conservative investors seeking safe investments.
- Dividend Attractiveness: Medtronic has increased its dividend for 48 consecutive years, demonstrating financial health and stability, and despite market challenges, it continues to provide reliable cash flow for investors, making it suitable for long-term holding.
See More
Intuitive Surgical Faces Competition from Medtronic's New Surgical Robot
- Increased Market Competition: Intuitive Surgical has 11,395 da Vinci systems installed globally, a 12% year-over-year increase, while Medtronic has just launched its Hugo surgical robot, which could become a significant growth engine in the coming years, intensifying market competition.
- Revenue Structure Analysis: In Q1, only 24% of Intuitive Surgical's revenue came from new system sales, with the remainder from services and accessories, highlighting the strength of its business model, although with a high P/E ratio of 55, investors should proceed with caution.
- Stock Price Volatility Risk: Despite a 500% increase in Intuitive Surgical's stock price over the past decade, it has recently fallen over 20% from its 52-week high, indicating potential volatility risks associated with high valuations, particularly for conservative investors.
- Dividend Appeal: Medtronic offers a dividend yield of 3.6% and has increased its dividend for 48 consecutive years, demonstrating business stability and attractiveness, especially for conservative investors during periods of market volatility.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
Intuitive Surgical's Growth Driven by da Vinci Robots and Services
- Significant Sales Growth: Intuitive Surgical installed 431 da Vinci surgical systems in Q1 2026, up 17% from 367 a year earlier, indicating robust market demand and reinforcing its leadership in the surgical robotics sector.
- Diverse Revenue Sources: While da Vinci robot sales are strong, they account for only 23% of total revenue, with instruments and accessories making up a substantial 60%, highlighting the company's ongoing profitability from post-surgical services and product sales.
- Surgery Volume Increase: The number of surgeries performed with da Vinci robots rose 17% year-over-year in Q1 2026, significantly outpacing the 12% increase in robot installations, demonstrating strong demand that further drives accessory and service sales.
- Long-Term Revenue Potential: Intuitive Surgical's parts and services revenue has annuity-like characteristics, as the sale of additional accessories and services will continue to grow with each new da Vinci robot sold, creating a sustainable revenue growth model.
See More
Intuitive Surgical's Growth Beyond Robot Sales
- Strong Market Demand: In Q1 2026, Intuitive Surgical installed 431 da Vinci systems, a 17% increase from 367 a year earlier, indicating robust demand for surgical robots that drives ongoing company growth.
- Revenue Structure Analysis: Despite strong sales of da Vinci robots, they account for only 23% of total revenue, while 60% comes from instruments and services, highlighting the company's ongoing profitability in post-surgical support.
- Surgery Volume Growth: The number of surgeries performed with da Vinci robots increased by 17% year-over-year in Q1 2026, significantly outpacing the 12% growth in robot numbers, demonstrating strong surgical demand that further boosts sales of parts and services.
- Long-Term Profitability Model: Intuitive Surgical's parts and services revenue is annuity-like, meaning as more da Vinci systems are sold, the ongoing demand for parts and services will continue to grow, creating a powerful profit driver.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Comparative Analysis of Intuitive Surgical and Medtronic
- Business Model Advantage: Intuitive Surgical has installed 11,395 da Vinci surgical systems globally, reflecting a 12% year-over-year increase, while demand for robotic-assisted surgeries has surged by 17%, indicating strong market demand and sustained revenue potential.
- Revenue Structure Analysis: In Q1, only 24% of Intuitive Surgical's revenue came from new system sales, with the remainder driven by services and accessories, highlighting a business model reliant on ongoing service income that enhances the company's long-term financial stability.
- Market Opportunity for Medtronic: Medtronic's recently launched Hugo surgical robot is beginning to ramp up sales, and despite a 40% drop from its 2021 peak, its diversified business and stable dividend appeal to conservative investors seeking safe investments.
- Dividend Attractiveness: Medtronic has increased its dividend for 48 consecutive years, demonstrating financial health and stability, and despite market challenges, it continues to provide reliable cash flow for investors, making it suitable for long-term holding.
See More
Intuitive Surgical Faces Competition from Medtronic's New Surgical Robot
- Increased Market Competition: Intuitive Surgical has 11,395 da Vinci systems installed globally, a 12% year-over-year increase, while Medtronic has just launched its Hugo surgical robot, which could become a significant growth engine in the coming years, intensifying market competition.
- Revenue Structure Analysis: In Q1, only 24% of Intuitive Surgical's revenue came from new system sales, with the remainder from services and accessories, highlighting the strength of its business model, although with a high P/E ratio of 55, investors should proceed with caution.
- Stock Price Volatility Risk: Despite a 500% increase in Intuitive Surgical's stock price over the past decade, it has recently fallen over 20% from its 52-week high, indicating potential volatility risks associated with high valuations, particularly for conservative investors.
- Dividend Appeal: Medtronic offers a dividend yield of 3.6% and has increased its dividend for 48 consecutive years, demonstrating business stability and attractiveness, especially for conservative investors during periods of market volatility.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
Intuitive Surgical's Growth Driven by da Vinci Robots and Services
- Significant Sales Growth: Intuitive Surgical installed 431 da Vinci surgical systems in Q1 2026, up 17% from 367 a year earlier, indicating robust market demand and reinforcing its leadership in the surgical robotics sector.
- Diverse Revenue Sources: While da Vinci robot sales are strong, they account for only 23% of total revenue, with instruments and accessories making up a substantial 60%, highlighting the company's ongoing profitability from post-surgical services and product sales.
- Surgery Volume Increase: The number of surgeries performed with da Vinci robots rose 17% year-over-year in Q1 2026, significantly outpacing the 12% increase in robot installations, demonstrating strong demand that further drives accessory and service sales.
- Long-Term Revenue Potential: Intuitive Surgical's parts and services revenue has annuity-like characteristics, as the sale of additional accessories and services will continue to grow with each new da Vinci robot sold, creating a sustainable revenue growth model.
See More
Intuitive Surgical's Growth Beyond Robot Sales
- Strong Market Demand: In Q1 2026, Intuitive Surgical installed 431 da Vinci systems, a 17% increase from 367 a year earlier, indicating robust demand for surgical robots that drives ongoing company growth.
- Revenue Structure Analysis: Despite strong sales of da Vinci robots, they account for only 23% of total revenue, while 60% comes from instruments and services, highlighting the company's ongoing profitability in post-surgical support.
- Surgery Volume Growth: The number of surgeries performed with da Vinci robots increased by 17% year-over-year in Q1 2026, significantly outpacing the 12% growth in robot numbers, demonstrating strong surgical demand that further boosts sales of parts and services.
- Long-Term Profitability Model: Intuitive Surgical's parts and services revenue is annuity-like, meaning as more da Vinci systems are sold, the ongoing demand for parts and services will continue to grow, creating a powerful profit driver.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
